NDT Advance Access originally published online on March 22, 2005
Nephrology Dialysis Transplantation 2005 20(5):974-980; doi:10.1093/ndt/gfh735
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Beneficial effect of early initiation of lipid-lowering therapy following renal transplantation
1 National Hospital, Oslo, Norway, 2 University Hospital, Uppsala, Sweden, 3 Western Infirmary, Glasgow, UK, 4 Sahlgrenska University Hospital, Gothenburg, Sweden, 5 University Hospital, Helsinki, Finland, 6 Skejby Hospital, Aarhus, Denmark, 7 Universitätsklinikum Charité, Berlin, Germany, 8 University Health Network, Toronto Hospital, Toronto, Canada, 9 University Hospital, Leuven, Belgium, 10 University Hospital, Zürich, Switzerland and 11 Medical Department, Novartis, Basel, Switzerland
Correspondence and offprint requests to: Hallvard Holdaas, MD, Rikshospitalet, Sognsvannsvn 20, Oslo 0072, Norway. Email: hallvard.holdaas{at}rikshospitalet.no
Background. Renal transplant recipients have a significantly reduced life expectancy, largely due to premature cardiovascular disease. The aim of the current analysis was to investigate the importance of time of initiation of therapy after transplantation, on the benefits of statin therapy.
Methods. 2102 renal transplant recipients with total cholesterol levels of 4.0–9.0 mmol/l were randomly assigned to treatment with fluvastatin (n = 1050) or placebo (n = 1052) and followed for a mean time of 5.1 years. The end-points were major cardiac events. The average median time from transplantation to randomization was 4.5 years (range: 0.5–29 years).
Results. In patients starting treatment with fluvastatin <4.5 years after renal transplantation, the incidence of cardiac events was 4.6% over 5.1 years vs 9.2% in those on placebo (P = 0.007). Fluvastatin significantly reduced the risk of cardiac death and non-fatal myocardial infarction by 56% [risk ratio (RR): 0.44; 95% confidence interval (95% CI): 0.26–0.74; P = 0.002]. In a more detailed analysis patients were grouped into 2-year intervals (since the last transplantation). The frequency of cardiac death and non-fatal myocardial infarction was reduced by 3.2%, 5.1%, 9.6% and 8.2% with fluvastatin treatment as compared to 6%, 10.4%, 13.4% and 9.6% with placebo when treatment was initiated at 0–2, 2–4, 4–6 and >6 years, respectively. The risk reduction for patients initiating therapy with fluvastatin at years 0–2 (compared with >6 years) following transplantation was 59% (RR: 0.41; 95% CI: 0.18–0.92; P = 0.0328). This is also reflected in total time on renal replacement therapy: in patients in the first quartile (<47 months) fluvastatin use was associated with a risk reduction of 64% compared with 19% for patients in the fourth quartile (>120 months) (P = 0.033).
Conclusions. Our data support an early introduction of fluvastatin therapy in a population of transplant recipients at high risk of premature coronary heart disease.
Keywords: cardiac end-points; fluvastatin; renal transplant recipients
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  E. Ritz and C. Wanner Statin Use Prolongs Patient Survival after Renal Transplantation J. Am. Soc. Nephrol., November 1, 2008; 19(11): 2037 - 2040. [Full Text] [PDF]
|
|
|
|
 |
|
 A. C. Shirali and M. J. Bia Management of Cardiovascular Disease in Renal Transplant Recipients Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 491 - 504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. van Ree, L. H. Oterdoom, A. P. J. de Vries, R. T. Gansevoort, J. J. H. van der Heide, W. J. van Son, R. J. Ploeg, P. E. de Jong, R. O. B. Gans, S. J. L. Bakker, et al. Elevated levels of C-reactive protein independently predict accelerated deterioration of graft function in renal transplant recipients Nephrol. Dial. Transplant., January 1, 2007; 22(1): 246 - 253. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Molitch Management of Dyslipidemias in Patients with Diabetes and Chronic Kidney Disease Clin. J. Am. Soc. Nephrol., September 1, 2006; 1(5): 1090 - 1099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Bergman, J. Burke, P. Larson, A. O. Johnson-Levonas, L. Reyderman, P. Statkevich, T. Kosoglou, H. E. Greenberg, W. K. Kraft, G. Frick, et al. Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects. J. Clin. Pharmacol., March 1, 2006; 46(3): 321 - 327. [Abstract] [Full Text] [PDF]
|
|